Q2 and H1 FY27 revenue rises 19% and 18%

Investor Communications View source PDF Explain this filing

WINDLAS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+8.7%Reaction day

₹918.00

prior close

₹914.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is usedpendingvs market: pending

Pharmaceuticals peers, median of 173sector-0.3%+9.0% vs sector

On the reaction day the stock moved 9.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+6.6

10m

+6.9

15m

+10.4

30m

+10.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+8.7pendingpending-0.3+9.0

Next day

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 FY27 revenue rose 19% to Rs 264 crore and H1 FY27 revenue rose 18% to Rs 512 crore. The main contract manufacturing business grew 32% in H1 to Rs 422 crore; trade generics fell 31% to Rs 66 crore, while exports rose 46% to Rs 23 crore. Adjusted EBITDA rose 23% to Rs 70 crore at 13.7%, and adjusted profit after tax rose 33% to Rs 50 crore. Plant-6 was commercialized; net liquidity was Rs 223 crore after a Rs 47 crore buyback and Rs 13 crore dividend.

Likely market impact

Strong growth and net liquidity support the outlook, but reported margins fell because H1 FY27 included Rs 14.06 crore of non-cash ESOP charges.